A case of severe thrombocytopenia after the first exposure to rifampicin.
Respir Med Case Rep
; 42: 101823, 2023.
Article
in En
| MEDLINE
| ID: mdl-36915472
ABSTRACT
Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 103/µL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Respir Med Case Rep
Year:
2023
Document type:
Article
Affiliation country:
Japan